Quantum-Si

Quantum-Si, Inc. develops a protein sequencing platform of proteomics. It offers single molecule analysis, and democratizing its use by providing researchers and clinicians access to the proteome. The company was founded by Jonathan M. Rothberg on June 24, 2013 and is headquartered in Guilford, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quantum-Si reports mixed Q4 results, eyes growth with Carbon launch

Quantum-Si's Q4 2022 earnings call showcased a mix of financial challenges and operational successes. The company's focus on innovation, product development, and commercialization efforts positions it well for future growth and impact in the healthcare industry.

Quantum-Si reports Q1 revenue growth, plans marketing expansion

Quantum-Si's Q1 2023 performance showed promising revenue and customer orders, but challenges persist with high operating expenses leading to an EBITDA loss. The company's focus on innovation and market expansion presents growth opportunities in the coming quarters.

Quantum-Si faces revenue hurdles in Q2 2023 earnings call

Quantum-Si's Q2 2023 performance showed revenue and gross profit figures, but challenges in meeting expectations led to significant losses. The company's strengths lie in the commercial team's positive feedback and strategic hires, while opportunities exist in realignment and disciplined growth strategies. Addressing revenue challenges, R&D alignment, and customer feedback are key priorities for Quantum-Si.

Quantum-Si (QSI) reports Q3 revenue growth and eyes global expansion

Quantum-Si (QSI) shows promising progress in revenue growth, product innovation, and market interest, despite facing challenges in expenses and profitability.
The company's strategic focus on commercializing key products and expanding internationally presents significant growth opportunities in the coming quarters.
Overall, QSI's financial performance, product roadmap, and market strategies position it for future success, pending effective execution and cost management.

Quantum-Si reports Q4 loss, eyes growth with innovative sequencing

Quantum-Si's Q4 2023 performance reflects a focus on innovation and market expansion despite a net loss, with strong revenue guidance for 2024.
The company's strategic strengths lie in its disruptive technology, product development initiatives, and market positioning in key regions.
Challenges in managing expenses and achieving profitability underscore the need for operational efficiency and competitive differentiation.
Amidst challenges, Quantum-Si has opportunities to drive growth through new product launches, market expansion, and meeting increasing market demand.

Quantum-Si reports revenue growth and strategic priorities for 2024

Quantum-Si's Q2 2024 performance showed revenue growth and improved net loss.
The company's strengths lie in financial reserves, guidance, and strategic priorities.
Challenges include managing expenses and balancing financial strength with innovation.
Opportunities arise from new board additions, technology potential, and market focus.

Quantum-Si reports Q3 revenue miss, eyes growth opportunities ahead

Quantum-Si's Q3 2024 performance reflects revenue challenges but anticipates improvement in Q4, supported by strong cash reserves.
The company's strategic strengths include leadership appointments, industry recognition, and initiatives to drive technology adoption.
Addressing challenges in deal execution, cost management, and revenue generation will be crucial for Quantum-Si's financial health and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quantum-Si, Inc. engages in the development of a proprietary universal single-molecule detection platform to enable Next-Generation Protein Sequencing, the ability to sequence proteins in a massively parallel fashion. It can be used for the study of nucleic acids. Its platform includes Carbon automated sample preparation instrument, Platinum NGPS instrument, Quantum-Si Cloud software service, and reagent kits and chips for use with its instruments. The company was founded by Jonathan M. Rothberg on June 24, 2013 and is headquartered in Branford, CT.

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the Jefferies Healthcare Conference.

Quantum-Si to Participate in the Jefferies Healthcare Conference

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Appoints Life Sciences and Diagnostics Industry Leader Jack Kenny to its Board of Directors.

Quantum-Si Appoints Life Sciences and Diagnostics Industry Leader Jack Kenny to its Board of Directors

GUILFORD, Conn.--(BUSINESS WIRE)-- #theproteinsequencingcompany--Scott Mendel Elected to Quantum-Si Board of Directors.

Scott Mendel Elected to Quantum-Si Board of Directors

Quantum-Si's proprietary protein detection platform has begun generating revenue, although it's not expected to significantly affect the cash-burn rate immediately. The company's financial stability extends till 2026 at the current burn rate, but rapid revenue generation and financial discipline are vital for survival post-2025.

Assessing Quantum-Si's Path To Commercialization

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports First Quarter 2023 Financial Results.

Quantum-Si Reports First Quarter 2023 Financial Results

GUILFORD, Conn.--(BUSINESS WIRE)-- #theproteinsequencingcompany--Quantum-Si today announced the appointment of Jeff Keyes as its new Chief Financial Officer.

Quantum-Si Announces the Appointment of Jeff Keyes as Chief Financial Officer

GUILFORD, Conn.--(BUSINESS WIRE)-- #theproteinsequencingcompany--Quantum-Si bolsters executive leadership team with four key appointments.

Quantum-Si Bolsters Executive Leadership Team with Four Key Appointments

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will report financial results for the first quarter 2023 on Thursday, May 11, 2023. Company management will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET.

Quantum-Si to Report First Quarter 2023 Financial Results on May 11, 2023

GUILFORD, Conn.--(BUSINESS WIRE)-- #theproteinsequencingcompany--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced it will be presenting a poster on a new method for detection of arginine post-translational modifications (PTMs) using Platinum™, the world's first next-generation single-molecule protein sequencing platform, at the American Association for Cancer Research's (AACR) Annual Meeting 2023.

Quantum-Si To Present Poster on Single-Molecule Method for Detection of Arginine Post-Translational Modifications at the AACR Annual Meeting 2023

Quantum-Si incorporated (NASDAQ:QSI ) Q4 2022 Results Conference Call March 6, 2023 8:30 AM ET Company Participants Juan Avendano - Head, Investor Relations Jeff Hawkins - Chief Executive Officer Patrick Schneider - President and Chief Operating Officer Claudia Drayton - Chief Financial Officer Conference Call Participants Alex Vukasin - Canaccord Genuity Yuan Zhi - B. Riley Operator Ladies and gentlemen, thank you for standing by.

Quantum-Si incorporated (QSI) Q4 2022 Earnings Call Transcript

GUILFORD, Conn.--(BUSINESS WIRE)--March 6, 2023--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022.

Quantum-Si Reports Fourth Quarter and Fiscal Year 2022 Financial Results

GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in the 43rd Annual Cowen Health Care Conference taking place at the Boston Marriott Copley Place, Boston, MA on March 6-8, 2023.

Quantum-Si to Participate in the 43rd Annual Cowen Health Care Conference

Quantum-Si to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

GUILFORD, Conn.--( BUSINESS WIRE )--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that management will discuss the following business updates at the 41st Annual J.P. Morgan Healthcare Conference.

Quantum-Si Begins Commercial Shipments of the PlatinumTM Protein Sequencing System and Provides Business Updates at the 41st Annual J.P. Morgan Healthcare Conference

GUILFORD, Conn.--( BUSINESS WIRE )--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it entered into a partnership and license agreement with Biovista to provide customers greater proteomic insights beyond their protein sequence output. Biovista leverages AI in multiple formats to analyze massive data repositories and visualize non-obvious networks and associations between proteins, diseases, and drug mechanisms-of-action. The partnership enhances Quantium-Si's offering by making proteomic-to-drug workflows more efficient for researchers.

Quantum-Si and Biovista Partner to Provide AI-Driven Deep Proteomics Insights from the Platinum™ Next-Generation Protein Sequence Platform Output

GUILFORD, Conn.--( BUSINESS WIRE )--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it entered into a partnership with Aviva Systems Biology, a leading provider of antibody, protein, and immunoassay reagent products with an extensive portfolio of over 20,000 antibodies against more than 15,000 human gene targets. This partnership seeks to co-develop protein enrichment kits to enable deep interrogation of proteins of interest and their variants (proteoforms) through protein sequencing.

Quantum-Si and Aviva Systems Biology Partner to Co-Develop Sample Preparation Kits for Protein Sequencing

Quantum-Si's technology has potential in drug discovery and biomarker test development. The company's Platinum sequencing platform is set to launch.

Revolutionizing Protein Sequencing: Quantum-Si's Single-Molecule Technology

GUILFORD, Conn.--( BUSINESS WIRE )--Dec. 22, 2022--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will be participating in the 41st Annual J.P. Morgan Healthcare Conference taking place at the Westin St. Francis, San Francisco, CA on January 9-12, 2023.

Quantum-Si to Participate in the 41st Annual J.P. Morgan Healthcare Conference

GUILFORD, Conn.--( BUSINESS WIRE )--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the commercial availability of Platinum™, the world's first next-generation single-molecule protein sequencing platform. Platinum will be offered at an unprecedented low price-point of $70,000, while its small 19.5 inch by 8.5 inch footprint benchtop design is poised to greatly improve access to high-resolution protein sequencing data, ultimately accelerating breakthroughs across scientific disciplines—from drug discovery to biotech—and helping people live healthier and longer lives.

Quantum-Si Announces Commercial Availability of PlatinumTM, the World's First Next-Generation Single-Molecule Protein Sequencing Platform

GUILFORD, Conn.--( BUSINESS WIRE )--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced it has joined the Human Proteome Organization (HUPO) Industrial Advisory Board (IAB), an international scientific organization focused on fostering collaboration and promoting new technologies in the proteomics sphere. Dan Hanson, Director of Product, and Dr. Brian Reed, Head of Research, will represent Quantum-Si and support HUPO's mission to advance proteomics technologies, techniques and training to better understand human disease.

Quantum-Si Joins Human Proteome Organization (HUPO) Industrial Advisory Board

Cyxtera Technologies

It's a good time to start looking for millionaire-maker penny stocks. Inflationary pressures are starting to come down, and the market has started to creep higher.

3 Millionaire-Maker Penny Stocks You Will Regret Not Buying This Year

Quantum-Si incorporated (NASDAQ:QSI ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Juan Avendano - Head, Investor Relations Dr. Jonathan Rothberg - Founder and Chairman Jeff Hawkins - Chief Executive Officer Patrick Schneider - President and COO Claudia Drayton - Chief Financial Officer Conference Call Participants Alex Vukasin - Canaccord Genuity Brandon Carney - B. Riley Operator Ladies and gentlemen, thank you for standing by.

News for Quantum-Si Stock (QSI)